
| ID | 69578 |
| フルテキストURL | |
| 著者 |
Ishiyama, Ken
Department of Hematology, Kanazawa University Hospital
Yamazaki, Masahide
Department of Internal Medicine, Keiju Medical Center
Maruyama, Hiroyuki
Department of Hematology, Kanazawa University Hospital
Hosono, Naoko
Department of Hematology and Oncology, University of Fukui Hospital
Yamaguchi, Hiroki
Department of Hematology, Nippon Medical School
Asada, Noboru
Department of Hematology and Oncology, Okayama University Hospital
Kaken ID
researchmap
Tanimoto, Kazuki
Department of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital
Sugiura, Hiroyuki
Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers
Usuki, Kensuke
Department of Hematology, NTT Medical Center Tokyo
Yoshimura, Kenichi
Department of Biostatistics and Health Data Science, Graduate School of Medical Science, Nagoya City University
Ogawa, Seishi
Department of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University
Kanakura, Yuzuru
Sumitomo Hospital
Matsumura, Itaru
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
Akashi, Koichi
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences
Nakao, Shinji
Department of Hematology, Kanazawa University Hospital
|
| 抄録 | The efficacy of ciclosporin (CsA) to treat transfusion-independent non-severe aplastic anaemia (TI-NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI-NSAA treated with CsA monotherapy. CsA (3.5 mg/kg/day) was administered to patients with TI-NSAA aged ≥16. The CsA dose was adjusted to maintain a blood CsA level of ≥600 ng/mL at 2 h post-administration. Blood cell counts were assessed after 8, 16 and 52 weeks of therapy. Thirty-two evaluable patients from 21 institutions were enrolled. The median age was 63.5 (range: 16–83) years. At 8 weeks, haematological improvement, with increases in haemoglobin (Hb) ≥1.5 g/dL (haematological improvement in erythrocytes [HI-E]) and platelet count ≥30 × 109/L (haematological improvement in platelets [HI-P]), was observed in 0/25 (0%) and 6/32 (19%) evaluable cases respectively. HI-E and HI-P occurred in 1/25 (4%) and 10/32 (31%) patients at 16 weeks, respectively, and at 52 weeks in 5/25 (20%) and 16/32 (50%) patients respectively. Nine grade 3 adverse events (AEs) occurred in six patients, but there were no grade ≥4 AEs. Ten of the 32 patients experienced grade 2 renal toxicity. Low-dose CsA is effective in TI-NSAA patients and demonstrates minimal renal toxicity. However, at least 16 weeks are necessary to adequately evaluate its efficacy.
|
| キーワード | ciclosporin
prospective study
renal toxicity
transfusion-independent non-severe aplastic anaemia
|
| 発行日 | 2025-09-08
|
| 出版物タイトル |
British Journal of Haematology
|
| 出版者 | Wiley
|
| ISSN | 0007-1048
|
| NCID | AA00574570
|
| 資料タイプ |
学術雑誌論文
|
| 言語 |
英語
|
| OAI-PMH Set |
岡山大学
|
| 著作権者 | © 2025 The Author(s).
|
| 論文のバージョン | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| 関連URL | isVersionOf https://doi.org/10.1111/bjh.70144
|
| ライセンス | http://creativecommons.org/licenses/by-nc-nd/4.0/
|
| Citation | Ishiyama K, Yamazaki M, Maruyama H, Hosono N, Yamaguchi H, Asada N, et al. Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study. Br J Haematol. 2025; 00: 1–9. https://doi.org/10.1111/bjh.70144
|
| 助成情報 |
( 一般社団法人九州臨床研究支援センター / Clinical Research Support Center Kyushu )
|